Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1986-11-04
1991-07-16
Schwartz, Richard A.
Chemistry: molecular biology and microbiology
Spore forming or isolating process
435 691, 435 701, 435 91, 4351721, 4351723, 4352351, 435236, 4352401, 4353201, 536 27, 935 6, 935 8, 935 9, 935 11, 935 22, 935 23, 935 32, 935 47, 935 48, 935 59, 935 60, 935 63, C12N 701, C12N 510, C12N 1550, C12N 1586
Patent
active
050325205
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the spike protein of infectious bronchitis virus (IBV) and to a recombinant DNA method for preparing it. IBV is a virus which causes respiratory disease in the fowl, and is of particular importance in relation to poultry.
2. Description of the Prior Art
IBV is a virus of the type Coronaviridae. It has a single-stranded RNA genome, approximately 20 kb in length, of positive polarity, which specifies the production of three major structural proteins: nucleocapsid protein, membrane glycoprotein, and spike glycoprotein. The spike glycoprotein is so called because it is present in the teardrop-shaped surface projections or spikes protruding from the lipid membrane of the virus. The spike protein is believed likely to be responsible for immunogenicity of the virus, partly by analogy with the spike proteins of other corona-viruses and partly by in vitro neutralisation experiments, see, for example, D. Cavanagh et al., Avian Pathology 13, 573-583 (1984). Although the term "spike protein" is used to refer to the glycoproteinaceous material of the spike, it has recently been characterised by D. Cavanagh, Journal of General Virology 64, 1187-1191; 1787-1791; and 2577-2583 (1983) as comprising two or three copies each of two glycopolypeptides, S1 (90,000 daltons) and S2 (84,000 daltons). The polypeptide components of the glycopolypeptides S1 and S2 have been estimated after enzymatic removal of oligosaccharides to have a combined molecular weight of approximately 125,000 daltons. It appears that the spike protein is attached to the viral membrane by the S2 polypeptide.
The genomic organisation of the IBV viral proteins is summarised in, for example, T. D. K. Brown and M. E. G. Boursnell, Virus Research 1, 15-24 (1984). Briefly, six polyadenlyated IBV viral mRNA species (A to F) have been detected in infected cells. mRNA A is the smallest and mRNA F is of genome length. These mRNAs form a so-called `nested` or 3' co-terminal set. The nested mRNAs A to E have sizes approximately 2, 2.4, 3.4, 4.1 and 7.8 kb, as estimated from formaldehyde-agarose gel electrophoresis. They are shown in the accompanying drawing. Evidence from translation studies in vitro suggests that mRNAs A, C and E are each translated to give a corresponding major polypeptide. Thus, mRNA A codes for the nucleocapsid polypeptide, mRNA C for the membrane polypeptide and mRNA E for the precursor of the spike protein. In connection with mRNA E D. F. Stern and B. M. Sefton, Journal of Virology 50, 22-29 (1984) found that this mRNA specified production of the spike protein precursor in an in vitro translation. The sizes of the translation products are consistent with the coding capacity being present at the 5' end of each mRNA, but not present in the next smallest mRNA. In other words, the coding portion is within the "unique" region, i.e. the region of `non-overlap` between successive RNAs of the set. U.v. inactivation studies have demonstrated that the subgenomic mRNAs are not produced by processing of larger RNA species, but are synthesised independently.
DNA complementary to IBV RNA (hereinafter referred to as `cDNA`) has been obtained for the Beaudette strain of IBV, as two fragments, together encompassing the first 3.3 kb of RNA from the 3' end, extending nearly to the 5' end of mRNA C. The fragments were inserted in plasmids and cloned in E. coli. They are described as C5.136 and C5.322 in T. D. K. Brown and M. E. G. Boursnell, supra, C5.136 being that running from nucleotides 1000 to 3300 approximately. Sequence information on C5.136 from nucleotides 1630 to 2400 approximately and the cloning of cDNA for IBV Beaudette strain including mRNA B and the 5' region of mRNA A have been described by M. E. G. Boursnell and T. D. K. Brown, Gene 29, 87-92 (1984). Futher C5.136 sequence from nucleotides 2200 to 3400 approximately has been published by M. E. G. Boursnell, T. D. K. Brown and M. M. Binns, Virus Research 1, 303-313 (1984).
In the paper `Genetically Engineered Vaccine aga
REFERENCES:
patent: 4738846 (1988-04-01), Rose et al.
Mackett et al., 1984, J. Virol. 49(3):857-864.
Biological Abstract 78(2):12149 Brown et al., 1984 Avian Pathology 13(1):109-118, "Confirmation of the Presence of Avian Infectious Bronchitis Virus Using Cloned DNA Complementary to the 3' Terminus of the Infectious Bronchitis Virus Genome".
Chemical Abstracts 101:144896y Genetically Engineered Vaccine Against Avian Infectious Bronchitis Virus with the Advantages of Current Live and Killed Vaccines, Cavanagh et al. 1984 in: Mod. Approaches Vaccines: Mol. Chem. Basis Virus Virulence Immunogenicity, Cold Spring Harbor Lab., N.Y. 215-218.
Chemical Abstracts 101:164558t, Sequence of the Membrane Protein Gene from Avian Coronavirus IBV. Virus Res. 1984 1(4):303-313 (Eng.).
Chemical Abstracts 102:179970r DNA Sequencing Studies of Genomic cDNA Clones of Avian Infectious Bronchitis Virus, Boursnell et al., Adv. Exp. Med. Biol. 1984, 173(Mol. Biol. Pathog. (Coronaviruses).
M. E. G. Boursnell et al., 1984 Gene 29:87-92.
Stern et al., 1984, J. Virol. 50:22-29.
D. Cavanagh et al., Avian Pathology 13, 573-583 (1984).
D. Cavanagh, Journal of General Virology, 64, 1187-1191 (1983).
D. Cavanagh, Journal of General Virology, 64, 1787-1791 (1983).
D. Cavanagh, Journal of General Virology, 64, 2577-2583 (1983).
T. D. K. Brown et al., Virus Research, 1, 15-24 (1984).
J. K. A. Cook, The Veterinary Record 112, 104-105 (1983).
J. K. A. Cook, Avian Pathology 13, 733-741 (1984).
M. M. Binns et al., J. Gen. Virol. 66, 719-726, (1985).
D. Cavanagh, Poultry International, 80-82 (Oct. 1984).
Animal Pharm. 69, 15 (Nov. 30, 1984).
Report of the Houghton Poultry Research Station 1981-1982, pub. Houghton Poultry Research Station, Houghton, Huntingdon, Cambs. UK, (1983), pp. 49 to 51.
Report of the Houghton Poultry Research Station 1983-1984, pub. Houghton Poultry Research Station, Houghton, Huntingdon, Cambs, UK (1985), pp. 48 to 50.
M. M. Binns et al., J. Virological Methods 11, 265-269 (1985).
T. D. K. Brown et al., Avian Pathology 13, 109-117 (1984).
T. D. K. Brown et al., Journal of General Virology 65, 1437-1442 (1984).
M. E. G. Boursnell et al., Journal of General Virology 66, 573-580 (1985).
M. E. G. Boursnell et al., Journal of General Virology 66, 2253-2258 (1985).
I. Brierley et al., EMBO J., 6, 3779-3785 (1987).
E. G. Strauss et al., Virology 133, 92-110 (1984).
L. Yuen & B. Moss, Proc. Natl. Acad. Sci. U.S.A., 84, 6417-6421 (1987).
Binns Matthew M.
Boursnell Michael E. G.
Brown Thomas D. K.
Tomley Fiona M.
National Research Development Corporation
Peet Richard
Schwartz Richard A.
LandOfFree
DNA sequences encoding infectious bronchitis virus spike protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA sequences encoding infectious bronchitis virus spike protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA sequences encoding infectious bronchitis virus spike protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-131288